The behaviour of the peripheral natural killer cells in the foetal growth restriction.

AIM: To study the behaviour of the peripheral lymphocyte subsets in foetuses affected by growth restriction. PATIENTS AND METHODS: Thirty consecutive pregnant women with an ultrasound diagnosis of foetal growth restriction were included in this study (group A) while 30 women with a physiologic pregnancy were recruited as control group (group B). The diagnosis was performed during the ultrasound of the third trimester and confirmed at birth. Blood samples were drawn after the ultrasound of the third trimester for all patients. The analyzed populations were: WBC, total lymphocytes, CD2+, CD3+, CD4+, CD5+, CD8+, CD19+, CD56+, HLA-DR+, CD45+, CD3+HLA-DR+, CD4+CD3+, CD3+CD8+, CD2+CD56+, CD19+CD5+, ratio (CD4+CD3+)/(CD3+CD8+). RESULTS: The percentage and absolute value of the NK cells was higher in the group A [(20.90 vs. 15.09)%, p = 0.0005; (419.55 vs. 341.40) UI/µl, p = 0.0005]. This trend was confirmed by the CD2+CD56+ natural killer (NK) subset [(18.84 vs. 13.42) UI/µl, p = 0.0005]. Instead, the CD4+ percentage value was lower in the group A [(41.15 vs. 44.84)%, p = 0.03] through the CD4+CD3+/CD3+CD8+ ratio was not significantly different. CONCLUSIONS: Our findings reinforce the concept of pregnancy as a controlled systemic inflammatory state that if altered can have adverse consequences for the mother and the foetus.

Low dose of betamethasone throughout the whole course of pregnancy and fetal growth: a clinical study.

AIM: To assess the eventual influence of low dose betamethasone throughout pregnancy on fetal growth. PATIENTS AND METHODS: 320 patients - admitted to the Section of Obstetrics and Gynecology of Ferrara University from January 2005 to December 2010 - were subdivided in two groups: 160 patients affected by recurrent spontaneous abortion (Group A), treated by low dose of betamethasone (0.5 mg/daily) throughout pregnancy for preventive purposes, 160 patients with physiological pregnancy as control group (Group B). Primary measured outcomes were neonatal biometric parameters such as birth weight, head circumference and neonatal length. Unpaired t-test was used to compare the neonatal biometric parameters. RESULTS: Birth weight, length and circumference head resulted significantly lower in groups treated by GCs. However, excluding bias as pregnancy complicated by diseases, which could affect fetal growth, biometric neonatal parameters were not different between two groups. Furthermore, analyzing the distribution of the value of birth weight we observed that in the group A there were 44 newborns with a weight even higher than fiftieth percentile. CONCLUSIONS: Betamethasone seems not to influence fetal growth. Our analysis demonstrates that fetal growth is influenced by several factors, therefore, homogeneous study population is essential to have convincing results.

Pancreatic cancer with liver metastases in a pregnant patient: case report and review of the literature.

In this case report, the authors discuss clinical presentation, surgical procedure and early results of chemotherapy of pancreatic carcinoma with liver metastases diagnosed a few days after delivery. Pancreatic adenocarcinoma occurs infrequently in pregnant and childbearing women: only ten cases have been reported in the literature. The early diagnosis of pancreatic cancer is difficult because symptoms appear when cancer is about to reach an advanced stage. In pregnancy, it is even more difficult because symptoms like dyspepsia, vomiting and epigastric pain may result confusing. The authors outline the difficulties in diagnosis and treatment of this kind of disease during pregnancy.

Porcine valve durability: a comparison between Hancock standard and Hancock II bioprostheses.

Two series of patients who received a Hancock standard (HS) (1970 to 1983) and a Hancock II (HII) (1983 to 1992) porcine bioprosthesis were reviewed to compare bioprosthetic durability. Patients with HS porcine bioprostheses (n = 769) differed from those with HII bioprostheses mostly in mean age at operation (47 +/- 12 versus 62 +/- 9 years; p < 0.001); the latter prosthesis was implanted mostly in patients older than 50 years. At 8 years after operation, actuarial survival was 57% +/- 4% after aortic, 61% +/- 3% after mitral, and 39% +/- 7% after mitral-aortic valve replacement with the HS bioprosthesis; actuarial survival was 51% +/- 9% after aortic, 66% +/- 6% after mitral, and 49% +/- 10% after mitral and aortic valve replacement with an HII bioprosthesis. No cases of structural deterioration of HII bioprostheses were observed at 8 years in any patients. Actuarial freedom from structural valve deterioration was 78% +/- 4% after aortic, 88% +/- 3% after mitral, and 79% +/- 7% after mitral-aortic valve replacement with an HS bioprosthesis at 8 years. In all patients greater than 50 years of age, actuarial freedom from structural valve deterioration at 8 years was 90% +/- 3% in patients with an HS bioprosthesis and 100% in those with an HII bioprosthesis (p = 0.08). A trend to an improved durability of the HII bioprosthesis compared with the HS was observed during the first 8 postoperative years. Because these results could be influenced partly by the age difference in the two series of patients, a longer follow-up is needed to confirm these data.

Early and late outcome after reoperation for prosthetic valve dysfunction: analysis of 549 patients during a 26-year period.

Factors influencing operative mortality and late survival of 549 patients undergoing a first reoperation for prosthetic valve failure during the interval from 1966 to 1992 were analyzed; 347 patients had reoperation on a mitral prosthesis, 173 on an aortic prosthesis and 29 on both aortic and mitral prostheses. Univariate analysis showed that hospital mortality was higher in patients in functional class IV compared with those in class II-III (35% vs. 8%, p < 0.001), in those who required emergency reoperation (57% vs. 11%, p < 0.001), in those reoperated for endocarditis (59%) or valve thrombosis (43%) compared with those reoperated for structural valve deterioration (9%, p < 0.001), and in those with a failing mechanical prosthesis compared to patients with a bioprosthesis (21% vs. 10%, p < 0.05). Furthermore, operative mortality decreased from 41% in the period from 1966 to 1977, to 12% from 1977 to 1983 and to 8% from 1984 to 1992 (p < 0.001). Hospital survivors were followed from 0.1 to 22 years (mean follow-up 11 +/- 5 years) with an overall actuarial survival at 15 years of 24 +/- 5%. At 15 years actuarial survival is 24 +/- 5% for patients in preoperative functional class II-III and 20 +/- 6% for those in functional class IV (p < 0.05). It is concluded that in prosthetic valve recipients both early and late outcome is greatly influenced by preoperative clinical status. Increasing surgical experience, better myocardial protection and patient management have contributed to reducing the operative risk. More accurate patient follow up and possibly earlier reoperation might also improve the long term outcome.

The Cabrol technique for replacement of the aortic valve and totally calcified ascending aorta: a case report.

Simultaneous replacement of the ascending aorta and aortic valve with a valved conduit was performed in a patient with aortic valve disease and totally calcified ascending aorta. Coronary circulation could be re-established by using the Cabrol technique, but only after extensive decalcification of the aortic wall surrounding the coronary ostia. This technique appears particularly suitable in patients who require combined replacement of the ascending aorta and aortic valve in the presence of diffuse calcification of the aortic root.

Annular enlargement during aortic valve replacement: preliminary results with a simplified technique.

A simplified technique has been used to enlarge the aortic annulus in a series of 13 patients undergoing aortic valve replacement. The procedure basically consists of extending the aortotomy incision into the aortic annulus by dividing the commissure between the left and noncoronary sinuses, without involving the anterior mitral leaflet. Wide opening of the commissure is obtained and the resulting defect is closed, preferably using a patch of bovine pericardium sutured to the mitral annulus and aortic wall. This technique is simple, reproducible, avoids opening of the left atrium (reducing the potential bleeding sites), allows insertion of a prosthesis at least two sizes larger than the original annulus, and is also applicable in cases of mitral-aortic valve replacement. Our preliminary results are satisfactory and seem to demonstrate that in many patients, even in the young age group, more complex procedures are often unnecessary when enlargement of the aortic annulus is required.

Heart valve replacement with the Sorin tilting-disc prosthesis. A 10-year experience.

From 1978 to 1988, 697 patients with a mean age of 48 +/- 11 years (range 5 to 75 years) received a Sorin tilting-disc prosthesis; 358 had had aortic valve replacement, 247 mitral valve replacement, and 92 mitral and aortic valve replacement. Operative mortality rates were 7.8%, 11.3%, and 10.8%, respectively, in the three groups. Cumulative duration of follow-up is 1650 patient-years for aortic valve replacement (maximum follow-up 11.4 years), 963 patient-years for mitral valve replacement (maximum follow-up 9.9 years) and 328 patient-years for mitral and aortic valve replacement (maximum follow-up 9.4 years). Actuarial survival at 9 years is 72% +/- 4% after mitral valve replacement, 70% +/- 3% after aortic valve replacement, and 50% +/- 12% after mitral and aortic valve replacement, and actuarial freedom from valve-related deaths is 97% +/- 2% after mitral valve replacement, 92% +/- 2% after aortic valve replacement, and 62% +/- 15% after mitral and aortic valve replacement. Thromboembolic events occurred in 21 patients with aortic valve replacement (1.3% +/- 0.2%/pt-yr), in 12 with mitral valve replacement (1.2% +/- 0.3% pt-yr), and in seven with mitral and aortic valve replacement (2.1% +/- 0.8%), with one case of prosthetic thrombosis in each group; actuarial freedom from thromboembolism at 9 years is 92% +/- 3% after mitral valve replacement, 91% +/- 3% after aortic valve replacement, and 74% +/- 16% after mitral and aortic valve replacement. Anticoagulant-related hemorrhage was observed in 15 patients after aortic valve replacement (0.9% +/- 0.2%/pt-yr), in 9 after mitral valve replacement (0.9% +/- 0.3%/pt-yr), and in 6 with mitral and aortic valve replacement (0.9% +/- 0.5%/pt-yr); actuarial freedom from this complication at 9 years is 94% +/- 2% after aortic valve replacement, 91% +/- 4% after mitral valve replacement, and 68% +/- 16% after mitral and aortic valve replacement. Actuarial freedom from reoperation at 9 years is 97% +/- 2% after mitral and aortic valve replacement, 92% +/- 4% after mitral valve replacement, and 89% +/- 3% after aortic valve replacement, with no cases of mechanical fracture. The Sorin valve has shown a satisfactory long-term overall performance, comparable with other mechanical prostheses, and an excellent durability that renders it a reliable heart valve substitute for the mitral and aortic positions.

The risk of reoperation in patients with bioprosthetic valves.

The risk of operative mortality in patients undergoing a first reoperation for bioprosthetic failure was assessed in a series of patients reoperated upon during the last two decades (1970-1990). A total of 330 such patients underwent replacement of 351 bioprostheses: 88 had aortic; 221 mitral; and 21 mitral and aortic bioprosthetic replacement. Indication for reoperation was in most cases structural valve deterioration (87%), followed by periprosthetic leak (7%) and endocarditis (6%). The operative mortality was significantly higher in patients who preoperatively were in New York Heart Association Functional Class IV or had a lower left ventricular function, in those reoperated because of prosthetic infection, and in those reoperated on an emergency basis. Structural valve deterioration was associated to a substantially low risk; operative mortality has improved in recent years, regardless of the indication for reoperation, partly due to the increasing experience and improved surgical techniques. Our results indicate that in recipients of bioprosthetic valves, careful follow-up with closer surveillance of valve and cardiac function and earlier prosthetic replacement might contribute to reducing the risk of reoperation.

Failure of Hancock pericardial xenografts: is prophylactic bioprosthetic replacement justified?

The incidence of major valve-related complications was evaluated in a series of patients in whom the Hancock pericardial xenograft was used for aortic (AVR; n = 84), mitral (MVR; n = 17) and mitral-aortic (MAVR; n = 13) valve replacement. At 7 years actuarial survival is 66% +/- 8% after AVR, 64% +/- 13% after MVR, and 41% +/- 15% after MAVR, whereas actuarial freedom from valve-related death is 79% +/- 7% after AVR, 78% +/- 13% after MVR, and 81% +/- 12% after MAVR. Actuarial freedom from thromboemboli and anticoagulant-related hemorrhage at 7 years is 93% +/- 4% and 98% +/- 2% after AVR and 83% +/- 10% and 88% +/- 11% after MVR; no such complications occurred after MAVR. Structural valve deterioration determined at reoperation, at autopsy, or by clinical investigation was observed in 34 patients with AVR (10.0 +/- 0.2%/patient-year), in 10 with MVR (10.6 +/- 3.3%/patient-year), and in 9 with MAVR (16.6 +/- 5.5%/patient-year). After AVR, 19 patients underwent reoperation and 2 died before reoperation; 4 patients with MVR underwent reoperation, and 7 patients with MAVR underwent reoperation and 1 died before reoperation. Seventy-eight percent of the current survivors (13 patients with AVR, 7 with MVR, and 1 with MAVR) have clinical evidence of valve failure. At 7 years actuarial freedom from structural deterioration of the Hancock pericardial xenograft is 25% +/- 7% after AVR, 29% +/- 14% after MVR, and 0% after MAVR.(ABSTRACT TRUNCATED AT 250 WORDS)